LEE011
Phase 2ActiveDevelopment Stage
Continued Access to Study Treatment(s), Cancers With a Mass, Bulky Tumor, Nodule, Lump, Advanced Cancer, Advanced Solid Tumors, Advanced Solid Malignancies
Continued Access to Study Treatment(s), Cancers With a Mass, Bulky Tumor, Nodule, Lump, Advanced Cancer, Advanced Solid Tumors, Advanced Solid Malignancies
Dec 15, 2016 → Feb 1, 2027
About LEE011
LEE011 is a phase 2 stage product being developed by Novartis for Continued Access to Study Treatment(s), Cancers With a Mass, Bulky Tumor, Nodule, Lump, Advanced Cancer, Advanced Solid Tumors, Advanced Solid Malignancies. The current trial status is active. This product is registered under clinical trial identifier NCT02934568. Target conditions include Continued Access to Study Treatment(s), Cancers With a Mass, Bulky Tumor, Nodule, Lump, Advanced Cancer, Advanced Solid Tumors, Advanced Solid Malignancies.
Hype Score Breakdown
Clinical Trials (8)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02934568 | Phase 2 | Active |
| NCT02524119 | Phase 2 | Terminated |
| NCT02431481 | Phase 1 | Completed |
| NCT02388620 | Phase 1 | Completed |
| NCT02187783 | Phase 2 | Completed |
| NCT01747876 | Phase 1 | Terminated |
| NCT01898845 | Phase 1 | Completed |
| NCT01237236 | Phase 1 | Completed |